Last reviewed: May 17, 2026
Last updated: May 17, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Shed and LifeMD are both established telemedicine platforms offering GLP-1 medications for weight management, but they differ fundamentally in provider oversight, compounding sourcing, and personalization methodology. Understanding these distinctions—alongside clinical factors like biomarker context and baseline health status—is essential for informed platform selection.
Choosing between telemedicine GLP-1 providers requires more than price comparison. Patients benefit from evaluating how platforms assess individual readiness, whether genetic or metabolic factors inform dosing strategy, and what safety guardrails exist. Precision-wellness approaches integrate biomarker insights to support more tailored provider-patient conversations.
Provider Model and Clinical Oversight Differences
Shed emphasizes direct provider partnerships with streamlined telemedicine visits, while LifeMD operates a broader marketplace model connecting patients to independent physicians. Both require medical evaluation before prescribing, but the continuity and personalization depth differ based on provider availability and caseload.
Provider model impacts follow-up frequency, medication adjustments, and safety monitoring. Direct partnerships typically enable tighter communication loops and faster response to side effects or efficacy questions. Marketplace models offer flexibility but may result in varied clinical depth across providers.
Compounding Sourcing and Cost Structure Comparison
Both platforms use compounded GLP-1 medications (typically semaglutide or tirzepatide) sourced from licensed compounding pharmacies, avoiding the premium pricing of branded drugs like Ozempic or Mounjaro. However, sourcing policies, quality assurance protocols, and transparency vary between platforms. Cost typically ranges from $150–$350 monthly depending on medication type and dosage.
Compounded medications from licensed 503A pharmacies offer cost savings versus branded alternatives, but pricing reflects sourcing standards, compounding facility oversight, and markup strategy. Comparing detailed ingredient sourcing, pharmacy licensing, and quality documentation helps patients understand value beyond headline pricing.
| Factor |
Shed Approach |
LifeMD Approach |
| Provider Model |
Direct partnerships with dedicated providers |
Marketplace connecting to independent physicians |
| Pharmacy Sourcing |
Licensed 503A compounding pharmacies |
Licensed 503A compounding pharmacies |
| Typical Pricing Range |
$150–$300 monthly for compounded GLP-1 |
$160–$320 monthly for compounded GLP-1 |
| Follow-up Frequency |
Provider-determined with ongoing access |
As-needed visits based on marketplace availability |
| Personalization Depth |
Provider-dependent; some assess lifestyle factors |
Varies by individual physician; less standardized |
Baseline Health Assessment and Contraindication Screening
Both platforms conduct medical evaluations to identify contraindications (personal or family history of medullary thyroid cancer, pancreatitis risk, renal impairment). However, the depth of metabolic assessment—weight loss history, comorbidities, medication interactions—varies. Detailed baseline screening supports safer, more effective dosing strategies.
Patients with complex medical histories benefit from platforms that thoroughly document appetite regulation pathways, insulin sensitivity patterns, and prior medication responses. This baseline context helps providers anticipate side effects and adjust dosing more proactively, reducing trial-and-error adjustments.
Genetic Predisposition Insights and Personalized Treatment Guidance
Neither Shed nor LifeMD currently integrates genetic predisposition screening into standard evaluation, though individual providers may recommend external testing. Understanding variants in GLP-1 signaling genes (GLP1R, GIPR), appetite regulation (FTO, MC4R), and metabolic pathways can provide clinical context for medication selection and dosing expectations.
Biomarker assessment and genetic predisposition screening represent an emerging layer in GLP-1 personalization. Patients seeking deeper insight into why a particular GLP-1 formulation or dosing strategy may align with their biology can discuss genetic testing as an adjunct to standard clinical evaluation. This information supports more targeted provider conversations without replacing clinical judgment.
How PlexusDx Supports a More Personalized Approach
PlexusDx differentiates by offering the Precision Peptide Genetic Test alongside compounded GLP-1 options, revealing predispositions in peptide-signaling pathways (GLP1R rs6923761, GIPR rs1800437) and metabolic genes (FTO rs9939609, MC4R rs17782313). This may help provide context for how individual physiology aligns with GLP-1 mechanisms, supporting more informed provider conversations about medication selection and expected response patterns.
The Precision Peptide Genetic Test ($99 add-on or $298 standalone) identifies genetic predispositions relevant to GLP-1 efficacy and tolerability, but it does not predict exact medication response or guarantee outcomes. Results should be interpreted with a qualified healthcare provider to inform individualized treatment strategy, dosing rationale, and side effect management expectations.
By combining compounded GLP-1 access with optional genetic predisposition screening, PlexusDx enables patients to evaluate both clinical factors (baseline health, contraindications) and biological context (genetic variants influencing GLP-1 signaling) before starting treatment. This integrated approach can support a more personalized conversation with your provider about which compounded formulation and dosing strategy aligns with your individual biology and health goals.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the main clinical difference between Shed and LifeMD?
Shed uses a direct provider partnership model with dedicated telemedicine physicians, while LifeMD operates a marketplace connecting patients to independent doctors. Both prescribe compounded GLP-1 medications, but provider continuity and oversight depth vary. Your choice depends on whether you prefer consistent provider relationships or marketp...
Are compounded GLP-1 medications from Shed or LifeMD FDA-approved?
Compounded semaglutide and tirzepatide are not FDA-approved as compounded products; they are compounded from pharmaceutical-grade ingredients at licensed 503A compounding pharmacies. While the active ingredients are well-studied, compounded formulations lack the pre-market approval and large-scale manufacturing oversight of branded drugs like Oz...
How does PlexusDx pricing compare to Shed or LifeMD?
PlexusDx compounded semaglutide ranges $149/mo and compounded tirzepatide $249/mo. Both Shed and LifeMD typically charge $150–$320 monthly. PlexusDx also offers the Microdose GLP-1 Protocol at $129/month and optional Precision Peptide Genetic Testing ($99 add-on) to inform personalized selection.
Should I consider genetic testing before choosing a GLP-1 platform?
Genetic predisposition testing is optional but may provide useful context. Variants in GLP1R, GIPR, FTO, and MC4R genes influence GLP-1 signaling efficiency and metabolic response. This information should be interpreted with your provider to inform medication choice and dosing expectations, but it does not replace standard medical evaluation or ...
What contraindications will Shed or LifeMD screen for?
Both platforms assess for personal or family history of medullary thyroid cancer, pancreatitis, severe renal impairment, and type 1 diabetes. Detailed evaluation of medications, comorbidities, and prior weight loss attempts varies by provider. Patients with complex histories should discuss baseline risk factors thoroughly to ensure safe, individ...
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Does Tirzepatide Work: Dual Receptor Action and Clinical Evidence
Ozempic Butt: Understanding Body Composition Changes During GLP-1 Therapy